Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer.
Ana Fernández MontesE ÉlezA VivancosN MartínezP GonzálezM CovelaJ de la CámaraA CousillasJ C MéndezB GrañaE ArandaPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2022)
Thirteen percentage of patients had undetectable RAS mutant clones in liquid biopsy after first-line treatment. However, some discrepancies between solid and liquid biopsies have been observed. These results suggest a need to improve accuracy of RAS analyses, especially in solid biopsies.